摘要
目的:探讨食管鳞癌术后替加氟联合奥沙利铂辅助化疗对患者生存率的影响。方法:82例食管鳞癌手术病例,31例术后未进行化疗(单纯组),51例术后替加氟联合奥沙利铂辅助化疗(化疗组)。比较两组1年、3年、5年生存期。结果:单纯手术组1年、3年、5年生存情况分别为22例(70.97%)、18例(58.06%)、14例(45.16%),化疗组1年、3年、5年生存情况分别为46例(90.19%)、37例(72.55%)、25例(49.02%)。化疗组生存情况优于单纯手术组,但两组间长期生存率差异无显著性。结论:替加氟联合奥沙利铂用于术后辅助化疗虽能提高切除食管鳞癌患者的生存情况,但差异无显著性,食管癌术后辅助化疗有效方案需进一步深入研究。
Objective：To explore the survival rate of adjuvant chemotherapy on postoperative esophageal squamous carcinoma for tegafur combined oxaliplatin adjuvant chemotherapy.Methods：82 cases of esophageal squamous carcinoma surgery cases,31 cases were no postoperative chemotherapy group （simple group）, 51 cases with postoperative for adjuvant chemotherapy with tegafur combined oxaliplatin （chemotherapy group）.Compared with two groups of 1 year,3 years,5 years survival.Results：Simple surgical group 1 year, 3 years, 5 years survival condition was 22 cases（70.97%）,18 cases（58.06%）,14 cases（45.16%） respectively, chemotherapy group 1 year,3 years,5 years survival condition was 46 cases （90.19%）, 37 cases （72.55%）, 25 cases （49.02%） respectively. Chemotherapy group survival situation was better than that of pure surgery group, but there was no significant difference between the two groups patients for 3 years and 5 years.Conclusion：Tegafur combined oxaliplatin for postoperative adjuvant chemotherapy can improve survival in patients with resected esophageal squamous carcinoma, but there was no significant difference, adjuvant chemotherapy after esophagectomy for patients with effective solutions, which need further in-depth study.
出处
《安徽卫生职业技术学院学报》
2014年第2期18-19,共2页
Journal of Anhui Health Vocational & Technical College
关键词
食管癌
辅助化疗
替加氟
奥沙利铂
Esophageal cancer Adjuvant chemotherapy Tegafur Oxaliplatin
